Overexpression of OTU Domain-containing Ubiquitin Aldehyde-binding Protein 1 Exacerbates Colorectal Cancer Malignancy by Inhibiting Protein Degradation of β-Catenin Via Ubiquitin-proteasome Pathway

Overview

Journal Bioengineered

Date 2022 Mar 31

PMID 35354355

Authors

Daoxiong Ye

Sisi Wang

Xiaojie Wang

Yu Lin

Ying Huang

Pan Chi

Affiliations

Soon will be listed here.

Abstract

Although major advances were achieved in colorectal cancer (CRC) therapy, major concerns still remain on proper control of cancer metastasis and chemo-resistance in order to achieve satisfactory general treatment response. Previous studies suggested that OTUB1 (OTU domain-containing ubiquitin aldehyde-binding protein 1) serves as regulator of gene ubiquitination and participates in the pathogenesis of multiple malignancies. Therefore, to discover its molecular mechanism in CRC tumor growth and metastasis will contribute in CRC treatment strategy development. Clinical tissues and CRC cancer cell lines were utilized to evaluate OTUB1 expression pattern. Functional tests including cellular proliferation, migration and invasion, as well as chemo-resistance, etc., were evaluated to investigate the role of OTUB1/β-catenin regulatory pathway on CRC malignant biological behaviors. Both CRC tumor tissues and CRC cell lines exhibited promoted OTUB1 expression level. Subsequent experiments further suggested that OTUB1 promoted CRC malignancy by enhancing protein stability of β-catenin, via inhibition of its protein degradation by UPP pathway, which indicated its crucial role in enhancement of CRC tumor cellular proliferative and chemo-resistant capabilities. This study reported that OTUB1 exhibited novel pro-survival and pro-metastatic function by interaction of β-Catenin via Ubiquitin-proteasome pathway. Our research indicated that OTUB1/β-Catenin regulatory axis might be potential druggable target for CRC cancer patients' treatment.

Citing Articles

Deubiquitinases as novel therapeutic targets for diseases.

Xian Y, Ye J, Tang Y, Zhang N, Peng C, Huang W MedComm (2020). 2024; 5(12):e70036.

PMID: 39678489 PMC: 11645450. DOI: 10.1002/mco2.70036.

Target deubiquitinase OTUB1 as a therapeatic strategy for BLCA via β-catenin/necroptosis signal pathway.

Liao Y, Liang J, Wang Y, Li A, Liu W, Zhong B Int J Biol Sci. 2024; 20(10):3784-3801.

PMID: 39113709 PMC: 11302878. DOI: 10.7150/ijbs.94013.

OTUB1 Promotes Glioblastoma Growth by Inhibiting the JAK2/STAT1 Signaling Pathway.

Yang J, Zhang N, He Z, Xiong J, Meng W, Xue C J Cancer. 2024; 15(14):4566-4576.

PMID: 39006090 PMC: 11242346. DOI: 10.7150/jca.96360.

Role of protein degradation systems in colorectal cancer.

Cui Z, Cong M, Yin S, Li Y, Ye Y, Liu X Cell Death Discov. 2024; 10(1):141.

PMID: 38485957 PMC: 10940631. DOI: 10.1038/s41420-023-01781-8.

Role of Post-Translational Modifications in Colorectal Cancer Metastasis.

Peng N, Liu J, Hai S, Liu Y, Zhao H, Liu W Cancers (Basel). 2024; 16(3).

PMID: 38339403 PMC: 10854713. DOI: 10.3390/cancers16030652.

References

Wang T, Yin L, Cooper E, Lai M, Dickey S, Pickart C . Evidence for bidentate substrate binding as the basis for the K48 linkage specificity of otubain 1. J Mol Biol. 2009; 386(4):1011-23. PMC: 2682458. DOI: 10.1016/j.jmb.2008.12.085. View

Zhu D, Xu R, Huang X, Tang Z, Tian Y, Zhang J . Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 2020; 28(6):1773-1789. PMC: 8184985. DOI: 10.1038/s41418-020-00700-z. View

Narayanankutty A . PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence. Curr Drug Targets. 2019; 20(12):1217-1226. DOI: 10.2174/1389450120666190618123846. View

Liu C, Li Y, Semenov M, Han C, Baeg G, Tan Y . Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002; 108(6):837-47. DOI: 10.1016/s0092-8674(02)00685-2. View

Baietti M, Simicek M, Abbasi Asbagh L, Radaelli E, Lievens S, Crowther J . OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination. EMBO Mol Med. 2016; 8(3):288-303. PMC: 4772950. DOI: 10.15252/emmm.201505972. View

Liao Y, Yang M, Wang K, Wang Y, Zhong B, Jiang N . Deubiquitinating enzyme OTUB1 in immunity and cancer: Good player or bad actor?. Cancer Lett. 2021; 526:248-258. DOI: 10.1016/j.canlet.2021.12.002. View

Hart M, Concordet J, Lassot I, Albert I, del los Santos R, Durand H . The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol. 1999; 9(4):207-10. DOI: 10.1016/s0960-9822(99)80091-8. View

Scaltriti M, Baselga J . The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006; 12(18):5268-72. DOI: 10.1158/1078-0432.CCR-05-1554. View

Sansom O, Meniel V, Muncan V, Phesse T, Wilkins J, Reed K . Myc deletion rescues Apc deficiency in the small intestine. Nature. 2007; 446(7136):676-9. DOI: 10.1038/nature05674. View

10.

Dejana E . The role of wnt signaling in physiological and pathological angiogenesis. Circ Res. 2010; 107(8):943-52. DOI: 10.1161/CIRCRESAHA.110.223750. View

11.

Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt J, Shima K, Nosho K . Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011; 305(16):1685-94. PMC: 3087286. DOI: 10.1001/jama.2011.513. View

12.

Liao Y, Wu N, Wang K, Wang M, Wang Y, Gao J . OTUB1 Promotes Progression and Proliferation of Prostate Cancer via Deubiquitinating and Stabling Cyclin E1. Front Cell Dev Biol. 2021; 8:617758. PMC: 7848094. DOI: 10.3389/fcell.2020.617758. View

13.

Bian J, Dannappel M, Wan C, Firestein R . Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer. Cells. 2020; 9(9). PMC: 7564852. DOI: 10.3390/cells9092125. View

14.

Lu Y, Xie S, Zhang W, Zhang C, Gao C, Sun Q . Twa1/Gid8 is a β-catenin nuclear retention factor in Wnt signaling and colorectal tumorigenesis. Cell Res. 2017; 27(12):1422-1440. PMC: 5717399. DOI: 10.1038/cr.2017.107. View

15.

De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P . Genetics, diagnosis and management of colorectal cancer (Review). Oncol Rep. 2015; 34(3):1087-96. PMC: 4530899. DOI: 10.3892/or.2015.4108. View

16.

Liu T, Jiang L, Tavana O, Gu W . The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11. Cancer Res. 2019; 79(8):1913-1924. PMC: 6467774. DOI: 10.1158/0008-5472.CAN-18-3037. View

17.

Patel M, Horgan P, McMillan D, Edwards J . NF-κB pathways in the development and progression of colorectal cancer. Transl Res. 2018; 197:43-56. DOI: 10.1016/j.trsl.2018.02.002. View

18.

Deng L, Wang C, Spencer E, Yang L, Braun A, You J . Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000; 103(2):351-61. DOI: 10.1016/s0092-8674(00)00126-4. View

19.

Nakada S, Tai I, Panier S, Al-Hakim A, Iemura S, Juang Y . Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature. 2010; 466(7309):941-6. DOI: 10.1038/nature09297. View